We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.13 | -2.82% | 4.48 | 4.48 | 4.49 | 4.5586 | 4.43 | 4.54 | 3,079,350 | 00:20:27 |
“At Novavax, we strive to create an environment where teamwork and collaboration thrive based on a culture that values and appreciates its employees,” said Stanley C. Erck, President and CEO. “We have an incredibly motivated team that is driven to improve global health through the development of safe and effective vaccines. We are committed to making Novavax one of the Top Workplaces for years to come.”
The Washington Post Top Workplaces are determined solely on employee feedback via an employee survey conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement.
Jill Hoyt, Vice President, Human Resources, said, “We are especially proud to be recognized because our talented and engaged workforce is our most important asset. We believe that all good outcomes begin with happy employees and we are honored to receive this recognition from the Washington Post for the third consecutive year.”
The Washington Post publishes the complete list of Top Workplaces on June 16, 2016. For more information about the Top Workplaces lists, please visit www.topworkplaces.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations ir@novavax.com 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. david.schull@russopartnersllc.com todd.davenport@russopartnersllc.com 212-845-4271
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions